NCT06761976 2026-03-30
Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation
Bayer
Available
Clinical Trials
23 trialsNCT06963697 2026-01-15
Expanded Access To Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors
Jaime Leandro Foundation for Therapeutic Cancer Vaccines
Available
NCT03626285 2026-01-02
Bone Marrow Transplantation Using CD34-Selected Stem Cells From Related or Unrelated Donors in Treating Participants With Cancer or Other Disorders
OHSU Knight Cancer Institute
Available
NCT02632994 2025-09-29
Master Rollover Protocol for Continued Safety Assessment of Study Drug
Eli Lilly and Company
Available
NCT06048081 2025-09-10
Early Access Program for Zolbetuximab
Astellas Pharma Inc
Available
NCT05162443 2025-08-26
Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation
Bristol-Myers Squibb
Approved for marketing
NCT06980506 2025-05-22
MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor Cancer
Monopar Therapeutics
Available
NCT06980519 2025-05-22
MNPR-101-PCTA-177Lu Expanded Access Program (EAP) for Patients With Solid Tumor Cancer
Monopar Therapeutics
Available
NCT05572970 2025-04-30
Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)
Agenus Inc.
Available
NCT02473497 2024-06-26
Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients
Pfizer
No longer available
NCT05014607 2024-05-09
InHeVac01
University Hospital Tuebingen
Available
NCT05119257 2024-05-08
InHeAb01
University Hospital Tuebingen
Available
NCT06238583 2024-02-02
Expanded Access to Provide Copanlisib for Patients With Cancer Who Are Experiencing a Positive Response, as Determined by Their Doctors
Bayer
No longer available
NCT03138629 2023-11-22
Expanded Access to VAL-083
Kintara Therapeutics, Inc.
No longer available
NCT04869501 2023-04-28
Expanded Access Study of TJ004309 in Patients With Advanced or Metastatic Cancer
I-Mab Biopharma US Limited
No longer available
NCT05491928 2022-09-01
Treatment of Metastatic Cancer in Terminally Diagnosed Patients
Matrix Biomed, Inc.
Available
NCT03126643 2021-11-29
Expanded Access to Nivolumab (Opdivo)
Bristol-Myers Squibb
Approved for marketing
NCT03206931 2021-09-16
Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion
Bayer
No longer available
NCT03529539 2019-03-06
PSV
EpicentRx, Inc.
No longer available
NCT02473653 2017-08-11
Pilot Trial of HER-2/Neu Pulsed DC1 Vaccine for Patients With HER-2 Positive Metastatic Cancer
University of Pennsylvania
No longer available
NCT01606982 2017-02-17
Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Astellas Pharma Inc
Approved for marketing
NCT01786850 2014-06-18
Magnetic Resonance-guided High-intensity Focused Ultrasound Treatment of Locally Advanced Pancreatic Cancer
University of Roma La Sapienza
Available
NCT00805337 2008-12-09
ADLG3
Pasche, Boris, M.D.
No longer available